Journal of the American Academy of Dermatology
Volume 59, Issue 5 , Pages 792-800 , November 2008

An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients

  • Diane Thiboutot, MD

      Affiliations

    • Department of Dermatology, the Pennsylvania State University College of Medicine, Hershey, Pennsylvania
    • ,
  • Andrea Zaenglein, MD

      Affiliations

    • Department of Dermatology, the Pennsylvania State University College of Medicine, Hershey, Pennsylvania
    • ,
  • Jonathan Weiss, MD

      Affiliations

    • Department of Dermatology, Gwinnett Clinical Research Center, Snellville, Georgia
    • ,
  • Guy Webster, MD, PhD

      Affiliations

    • Jefferson Dermatology Service, Wilmington Department of Veterans Affairs Medical Center, Wilmington, Pennsylvania
    • ,
  • Barry Calvarese, MS

      Affiliations

    • Dow Pharmaceutical Sciences Inc, Petaluma, California
    • ,
  • Diana Chen, MD

      Affiliations

    • Arcutis Pharmaceuticals, Redwood City, California
    • Corresponding Author InformationReprint requests: Diana Chen, MD, Medical Affairs, Arcutis Pharmaceuticals, 900 Island Drive, Suite 210, Redwood City, CA 94065.

,Accepted 24 June 2008.

References 

  1. White GM. Recent findings in the epidemiologic evidence, classification and subtypes of acne vulgaris. J Am Acad Dermatol. 1998;39(Suppl):S34–S37
  2. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: a report from the alliance to improve outcomes in acne. J Am Acad Dermatol. 2003;49(Suppl):S1–S38
  3. Webster GF, Jeyden JJ, McGinley KJ, McArthur WP. Suppression of polymorphonuclear leucocyte chemotactic factor production in Propionibacterium acnes by subminimal inhibitory concentrations of tetracycline, ampicillin, minocycline, and erythromycin. Antimicrob Agents Chemother. 1982;21:770–772
  4. Gupta AK, Lynde CW, Kunynetz RA, Amin S, Choi K, Goldstein E. A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. J Cutan Med Surg. 2003;7:31–37
  5. Waller JM, Dreher F, Behnam S, Ford C, Lee C, Tiet T, et al. Keratolytic properties of benzoyl peroxide and retinoic acid resemble salicylic acid in man. Skin Pharmacol Physiol. 2006;19:283–289
  6. Mills OH, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol. 1986;25:664–667
  7. Haustein UF, Tegetmeyer L, Ziegler V. Allergic and irritant potential of benzoyl peroxide. Contact Dermatitis. 1985;13:252–257
  8. Cunliffe WJ, Holland KT, Bojar R, Levy SF. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther. 2002;24:1117–1133
  9. Leyden J, Kaidby SF, Levy K. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. Am J Clin Dermatol. 2001;2:263–266
  10. Lookingbill DP, Chalker DK, Lindholm JS, Katz HI, Kempers SE, Huerter CJ, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol. 1997;37:590–595
  11. Tucker R, Walton S. The role of benzoyl peroxide in the management of acne vulgaris. Pharm J. 2007;279:48–53
  12. Serup J, Lindblad AK, Maroti M, Kjellgren KI, Niklasson E, Ring L, et al. To follow or not to follow dermatological treatment–a review of the literature. Acta Derm Venereol. 2006;86:193–197

 Supported by Arcutis Pharmaceuticals.

 Disclosure: Dr Thiboutot has been an investigator, consultant, or advisory board member for Allergan Inc, Arcutis Inc, Dusa Inc, Galderma Inc, Stiefel Inc, QLT Inc, and Medicis Inc, and has received honoraria or grant support. Dr Zaenglein has served as an advisory board member for Sanofi Aventis Inc, a speaker for Galderma Inc, an investigator for Arcutis Inc, and has received honoraria or grant support. Dr Weiss has served as an investigator and consultant for Arcutis Inc and has received grant support. Dr Webster has served as an investigator and consultant for Arcutis Inc, a consultant for Allergan Inc, Stiefel Inc, Sanofi Aventis Inc, Dusa Inc, Medicis Inc, Ortho Inc, QLT Inc, Galderma Inc, Coria Inc, Cutanea Inc, and has received honoraria or grant support. Mr Calvarese is an employee of Dow Pharmaceutical Sciences, Inc. Dr Chen is an employee of Arcutis Pharmaceuticals.

PII: S0190-9622(08)00806-2

doi: 10.1016/j.jaad.2008.06.040

Journal of the American Academy of Dermatology
Volume 59, Issue 5 , Pages 792-800 , November 2008

Article Tools

* Image Usage & Resolution